Ikena Oncology appoints Jotin Marango as COO; grants 400K option tied to strategic transaction

ImageneBio, Inc.

Jotin Marango appointed COO effective July 15, 2024, in addition to his roles as CFO and Head of Corporate Development.
Salary increased to $470,000 per year.
Granted option to purchase 400,000 shares vesting upon consummation of a strategic transaction.
Marango previously served as CFO since April 2022; prior roles at Aptose Biosciences and Roth Capital.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jotin Marango

Chief Operating Officer

IMA · ImageneBio, Inc.

Effective: 2024-07-15
Filed: July 12, 2024, 7:59 PM ET

On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jotin Marango was appointed as Chief Operating Officer at ImageneBio, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.

View on SEC.gov

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-178568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.